ProCE Banner Activity

Selecting Therapy for AML With Predictive Biomarkers or Actionable Alterations

Slideset Download

Download these slides from a live symposium for the most recent data on selecting AML therapy for patients with predictive biomarkers or actionable alterations.

Released: October 04, 2024

Expiration: August 01, 2025

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Astellas Text

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Servier Pharmaceuticals

Syndax

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M. Stein, MD: consultant/advisor/speaker: AbbVie, Agios, Aptose, Astellas, Blueprint, Bristol Myers Squibb, Calithera, CTI Biopharma, Daiichi Sankyo, Foghorn, Genentech, Genesis, Gilead, Janssen, Jazz Pharmaceuticals, Kura, Menarini, Neoleukin, Novartis, OnCusp, Ono Pharma, PinotBio, Servier, Syndax, Syros; data and safety monitoring board: Cellectis, Epizyme; researcher: Bristol Myers Squibb, Eisai; stock/stock options: Auron.

Presenter

Ananya Sharma

Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences
USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
and Keck School of Medicine
University of Southern California
Los Angeles. California